rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    DYN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Dyne Therapeutics to Participate in Upcoming Investor Conference
      Nov 11Yahoo FinanceDYN
      Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
      Nov 5Yahoo FinanceDYN
      Dyne downgraded at Oppenheimer on questions over myotonic dystrophy asset (DYN:NASDAQ)
      Oct 28Seeking AlphaDYNOPY
      Dyne Therapeutics earnings on deck as DMD approval looms
      Oct 28Investing.comDYN
      Oppenheimer Downgrades Dyne Therapeutics to Perform From Outperform, $15 Price Target
      Oct 28Yahoo FinanceDYN
      Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WALTHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 16 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity

      Oct 22Yahoo FinanceDYN
      Why Dyne Therapeutics (DYN) Is Back In The Spotlight
      Oct 7Yahoo FinanceDYN
      Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF) and Dyne Therapeutics (DYN)

      Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailDYN
      Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario (DYN)
      Sep 30Seeking AlphaDYN
      Stifel reiterates Dyne Therapeutics stock rating on trial data
      Sep 30Investing.comDYN
      Wainwright cuts Dyne Therapeutics stock price target on DM1 assumptions
      Sep 30Investing.comDYN
      Cantor Fitzgerald reiterates Dyne Therapeutics stock rating
      Sep 30Investing.comDYN
      Jefferies reiterates Dyne Therapeutics stock rating on trial data
      Sep 30Investing.comDYN
      Piper Sandler Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)

      Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

      Sep 30The Globe and MailDYN
      Dyne Therapeutics stock rises on positive DM1 trial results
      Sep 29Yahoo FinanceDYN
      Piper Sandler reiterates Dyne Therapeutics stock rating on drug approval confidence
      Sep 29Investing.comDYN
      Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
      Sep 29Yahoo FinanceDYN
      Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 14 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity

      Sep 17Yahoo FinanceDYN
      Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?

      Dyne Therapeutics announced it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial of zeleciment basivarsen for myotonic dystrophy type 1 at upcoming World Muscle Society and AANEM meetings in late September and early October 2026. The breadth of new functional and safety data, alongside details from a matched natural history cohort and a fully enrolled registrational expansion cohort, adds depth to Dyne’s emerging clinical story in DM1. We’ll now examine how...

      Sep 17Yahoo FinanceDYN
      Dyne Therapeutics at Morgan Stanley conference: launch plans take focus
      Sep 14Investing.comDYNMS
      Analysts Offer Insights on Healthcare Companies: Eocene (EOCN) and Dyne Therapeutics (DYN)

      Tipranks Press Release.

      Sep 11The Globe and MailDYN
      Dyne Therapeutics at Cantor conference: launch plans and pipeline expand
      Sep 11Investing.comDYN
      Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
      Sep 9Yahoo FinanceDYNNVS
      Dyne downgraded at J.P. Morgan on Novartis setback (DYN:NASDAQ)
      Sep 9Seeking AlphaDYNNVS
      Dyne Therapeutics stock price target lowered to $30 by RBC Capital
      Sep 9Investing.comDYN
      Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class (NASDAQ:DYN)

      Dyne Therapeutics lead asset z-rostudirsen faces regulatory and confirmatory risks, with FDA approval likely. Find out why DYN stock is a buy.

      Sep 9Seeking AlphaDYNNVS
      RBC Cuts Price Target on Dyne Therapeutics to $30 From $35, Keeps Outperform, Speculative Risk

      Dyne Therapeutics (DYN) has an average rating of buy and mean price target of $37.27, according to a

      Sep 9Yahoo FinanceDYN
      Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says

      Dyne Therapeutics (DYN) investment thesis remains intact despite a setback for Novartis (NVS) in a p

      Sep 9Yahoo FinanceDYN
      JPMorgan Downgrades Dyne Therapeutics to Underweight From Neutral, Cuts Price Target to $10 From $17

      Dyne Therapeutics (DYN) has an average rating of buy and mean price target of $37.27, according to a

      Sep 9Yahoo FinanceDYN
      Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
      Sep 8ReutersDYNSRPTNVS
      Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
      Sep 8BenzingaDYNNVS
      Raymond James cuts Dyne Therapeutics price target on DM1 trial risk
      Sep 8Investing.comDYN
      Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

      - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose portion of the trial to be compared against a matched natural history cohort - - Dyne also intends to provide the mean baseline value for video hand opening time (vHOT) in the ACHIEVE registrational expansion cohort (REC) in conjunction with these presentations - - Topline data from the ACHIEVE REC are on track for Q1 2027 - WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.

      Sep 8Yahoo FinanceDYN
      Dyne Therapeutics stock faces pressure after rival drug fails trial
      Sep 8Investing.comDYN
      Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed

      Dyne Therapeutics (NASDAQ:DYN) shares fell 31. 0% to $16.

      Sep 8Yahoo FinanceDNLIDYN
      Why is Dyne Therapeutics stock plummeting today?
      Sep 8Investing.comDYN
      Novartis drops 13% on trial failure, dragging Dyne and Sarepta (NVS:NYSE)

      Novartis stock sinks 13% after del-desiran phase 3 trial failed primary endpoints, sparking biotech selloff.

      Sep 8Seeking AlphaDYNSRPTNVS
      Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
      Sep 8BenzingaDYNIONSNVS
      Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting

      - Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All development candidates leverage the same FORCE™ platform as zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), which is under FDA review for exon 51 DMD - WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering funct

      Sep 3Yahoo FinanceDYN
      Dyne Therapeutics to Participate in Upcoming Investor Conferences

      WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference, fireside chat on Friday, September 11, 2026 at 10:20 a.m. ET in New York, NYMorgan Stanley 24th Annual Global Healthcare Con

      Sep 2Yahoo FinanceDYN

      This is the newest page. Registered accounts read further back.